Bladder and Urothelial Cancer Treatments

Bladder cancer, most commonly arising from the urothelial cells that line the bladder wall, is one of the more frequently diagnosed cancers worldwide and carries a high rate of recurrence that makes long-term management particularly demanding. Treatment ranges from intravesical immunotherapy with Bacillus Calmette-Guérin for early-stage disease to radical cystectomy and systemic chemotherapy for more advanced cases, with neoadjuvant chemotherapy before surgery now established as a standard approach for muscle-invasive tumors. Molecular characterization of urothelial carcinoma has revealed distinct subtypes with different prognoses and drug sensitivities, opening the door to more targeted therapies, though translating these genomic insights into consistent survival benefits—especially for patients with metastatic disease—remains an active and unsettled area of research. Improving patient selection for aggressive surgery versus bladder-sparing protocols, and identifying who responds to emerging immunotherapies, are among the central questions driving current clinical investigation.

Works

119,556

Total citations

1,332,013

Keywords

Bladder CancerUrothelial CarcinomaChemotherapyCystectomyBacillus Calmette-GuerinMolecular Characterization